Alpine Woods Capital Investors LLC Takes $1.31 Million Position in Precigen, Inc. $PGEN

Key Points

• Alpine Woods Capital Investors acquired 229,618 Precigen shares worth approximately $1.31 million, while hedge funds and other institutional investors collectively own 33.51% of the company.
• Precigen reported quarterly revenue of $54.98 million, up 6,322.7% year over year, and earnings of $0.05 per share—beating analysts’ estimate of a $0.01 loss. The stock opened at $6.75, near its 52-week high of $7.32.
• Analyst sentiment is mixed but leans positive: the consensus rating is “Moderate Buy” with an average price target of $14.50, while company insiders sold nearly 1 million shares worth $5.47 million over the past quarter.

Alpine Woods Capital Investors LLC bought a new stake in shares of Precigen, Inc. (NASDAQ:PGEN - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 229,618 shares of the biotechnology company's stock, valued at approximately $1,309,000. Alpine Woods Capital Investors LLC owned approximately 0.06% of Precigen as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Xponance LLC boosted its position in Precigen by 21.3% during the 4th quarter. Xponance LLC now owns 14,191 shares of the biotechnology company's stock valued at $59,000 after acquiring an additional 2,496 shares in the last quarter. BNP Paribas Financial Markets raised its position in shares of Precigen by 6.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 51,796 shares of the biotechnology company's stock worth $170,000 after acquiring an additional 2,993 shares in the last quarter. Composition Wealth LLC lifted its stake in shares of Precigen by 16.5% in the 4th quarter. Composition Wealth LLC now owns 21,217 shares of the biotechnology company's stock valued at $89,000 after purchasing an additional 3,000 shares during the period. Intech Investment Management LLC lifted its stake in shares of Precigen by 5.2% in the 4th quarter. Intech Investment Management LLC now owns 63,018 shares of the biotechnology company's stock valued at $263,000 after purchasing an additional 3,137 shares during the period. Finally, Cetera Investment Advisers boosted its position in shares of Precigen by 0.9% during the first quarter. Cetera Investment Advisers now owns 374,514 shares of the biotechnology company's stock valued at $1,449,000 after purchasing an additional 3,250 shares in the last quarter. 33.51% of the stock is owned by hedge funds and other institutional investors.

Precigen Trading Up 3.1%

NASDAQ:PGEN opened at $6.75 on Wednesday. The stock has a market cap of $2.41 billion, a price-to-earnings ratio of -6.49 and a beta of 1.02. The company has a quick ratio of 3.89, a current ratio of 4.58 and a debt-to-equity ratio of 2.15. The company's 50 day moving average price is $5.63 and its 200-day moving average price is $4.60. Precigen, Inc. has a 52 week low of $2.94 and a 52 week high of $7.32.

Precigen (NASDAQ:PGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share for the quarter, topping analysts' consensus estimates of ($0.01) by $0.06. The company had revenue of $54.98 million during the quarter, compared to analyst estimates of $27.98 million. Precigen had a negative net margin of 183.98% and a positive return on equity of 423.75%. Precigen's revenue was up 6322.7% on a year-over-year basis. On average, equities research analysts forecast that Precigen, Inc. will post 0.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, COO Rutul R. Shah sold 32,739 shares of Precigen stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $6.86, for a total value of $224,589.54. Following the completion of the sale, the chief operating officer directly owned 465,012 shares in the company, valued at approximately $3,189,982.32. This trade represents a 6.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Sabzevari sold 346,836 shares of the business's stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $5.89, for a total value of $2,042,864.04. Following the completion of the transaction, the chief executive officer directly owned 3,768,872 shares of the company's stock, valued at approximately $22,198,656.08. This trade represents a 8.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 989,239 shares of company stock valued at $5,472,960 over the last quarter. Corporate insiders own 41.40% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Zacks Research upgraded Precigen from a "hold" rating to a "strong-buy" rating in a report on Wednesday, August 5th. Wall Street Zen raised shares of Precigen from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 8th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Precigen in a research report on Friday, July 17th. HC Wainwright increased their price target on shares of Precigen from $14.00 to $18.00 and gave the stock a "buy" rating in a research note on Wednesday, August 5th. Finally, Citizens Jmp boosted their price target on Precigen from $9.00 to $11.00 and gave the stock a "market outperform" rating in a research report on Thursday, May 14th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Precigen currently has an average rating of "Moderate Buy" and an average target price of $14.50.

Precigen Company Profile

Precigen, Inc NASDAQ: PGEN is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen's approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen's technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source